The risk management of interstitial pneumonitis in cancer chemotherapy not only involves an adverse event by an anticancer drug, but there are four steps with the incidence of interstitial pneumonitis: 1) the time before chemotherapy treatment, selection of chemotherapy regimens and patients, 2) the time chemotherapy treatment is performed, 3) the time during following-up, 4) the time when interstitial pneumonitis occurs. It is necessary to decrease the risk of interstitial pneumonitis by several steps, cooperating with an entire medical staff.
|Number of pages||3|
|Journal||Japanese Journal of Cancer and Chemotherapy|
|Publication status||Published - Nov 2011|
All Science Journal Classification (ASJC) codes